Elevated Circulating Osteoprotegerin and Renal Dysfunction Predict 15-Year Cardiovascular and All-Cause Mortality: A Prospective Study of Elderly Women

被引:14
|
作者
Lewis, Joshua R. [1 ,2 ]
Lim, Wai H. [1 ,3 ]
Ueland, Thor [4 ]
Wong, Germaine [5 ]
Zhu, Kun [1 ,2 ]
Lim, Ee M. [2 ,6 ]
Bollerslev, Jens [7 ,8 ]
Prince, Richard L. [1 ,2 ]
机构
[1] Univ Western Australia, Sch Med & Pharmacol, Sir Charles Gairdner Hosp Unit, Perth, WA 6009, Australia
[2] Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Perth, WA, Australia
[3] Sir Charles Gairdner Hosp, Dept Renal Med, Perth, WA, Australia
[4] Oslo Univ Hosp, Rikshosp, Internal Med Res Inst, Oslo, Norway
[5] Univ Sydney, Sydney Med Sch, Sch Publ Hlth, Ctr Kidney Res,Childrens Hosp Westmead, Sydney, NSW 2006, Australia
[6] Sir Charles Gairdner Hosp, PathWest, Perth, WA, Australia
[7] Oslo Univ Hosp, Rikshosp, Dept Endocrinol, Sect Specialised Endocrinol, Oslo, Norway
[8] Univ Oslo, Oslo, Norway
来源
PLOS ONE | 2015年 / 10卷 / 07期
基金
英国医学研究理事会;
关键词
ATHEROSCLEROTIC VASCULAR-DISEASE; CORONARY-ARTERY CALCIFICATION; GLOMERULAR-FILTRATION-RATE; SMOOTH-MUSCLE-CELLS; SERUM OSTEOPROTEGERIN; PLASMA OSTEOPROTEGERIN; GENE POLYMORPHISMS; CALCIUM; EVENTS; 5-YEAR;
D O I
10.1371/journal.pone.0134266
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Data on the predictive role of estimated glomerular filtration rate (eGFR) and osteoprotegerin (OPG) for cardiovascular (CVD) and all-cause mortality risk have been presented by our group and others. We now present data on the interactions between OPG with stage I to III chronic kidney disease (CKD) for all-cause and CVD mortality. Methods and Results The setting was a 15-year study of 1,292 women over 70 years of age initially randomized to a 5-year controlled trial of 1.2 g of calcium daily. Serum OPG and creatinine levels with complete mortality records obtained from the Western Australian Data Linkage System were available. Interactions were detected between OPG levels and eGFR for both CVD and all-cause mortality (P < 0.05). Compared to participants with eGFR >= 60ml/min/1.73m(2) and low OPG, participants with eGFR of < 60ml/min/1.73m(2) and elevated OPG had a 61% and 75% increased risk of all-cause and CVD mortality respectively (multivariate-adjusted HR, 1.61; 95% CI, 1.27-2.05; P < 0.001 and HR, 1.75; 95% CI, 1.22-2.55; P = 0.003). This relationship with mortality was independent of decline in renal function (P < 0.05). Specific causes of death in individuals with elevated OPG and stage III CKD highlighted an excess of coronary heart disease, renal failure and chronic obstructive pulmonary disease deaths (P < 0.05). Conclusion The association between elevated OPG levels with CVD and all-cause mortality was more evident in elderly women with poorer renal function. Assessment of OPG in the context of renal function may be important in studies investigating its relationship with all-cause and CVD mortality.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Association of the dietary copper intake with all-cause and cardiovascular mortality: A prospective cohort study
    Wang, Lei
    Zhao, Yun-Tao
    PLOS ONE, 2023, 18 (10):
  • [42] Growth differentiation factor-15 is a biomarker for all-cause mortality but less evident for cardiovascular outcomes: A prospective study
    Bao, Xue
    Borne, Yan
    Xu, Biao
    Orho-Melander, Marju
    Nilsson, Jan
    Melander, Olle
    Engstrom, Gunnar
    AMERICAN HEART JOURNAL, 2021, 234 : 81 - 89
  • [43] Cardiovascular risk factors and 10-year all-cause mortality in elderly European male populations - The FINE study
    Menotti, A
    Mulder, I
    Nissinen, A
    Feskens, E
    Giampaoli, S
    Tervahauta, M
    Kromhout, D
    EUROPEAN HEART JOURNAL, 2001, 22 (07) : 573 - 579
  • [44] Joint association of cardiovascular health and frailty with all-cause and cause-specific mortality: a prospective study
    Ning, Ning
    Fan, Xiaoting
    Zhang, Yuan
    Wang, Yingxin
    Liu, Yang
    Li, Yumeng
    Zhao, Hua
    Jin, Lina
    Ma, Yanan
    AGE AND AGEING, 2024, 53 (07)
  • [45] Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy
    A. Jorsal
    L. Tarnow
    A. Flyvbjerg
    H.-H. Parving
    P. Rossing
    L. M. Rasmussen
    Diabetologia, 2008, 51 : 2100 - 2107
  • [46] SERUM URIC ACID LEVEL AND ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN HEMODIALYSIS PATIENTS: FIVE YEAR PROSPECTIVE OBSERVATIONAL STUDY
    Selim, Gjulsen
    Stojceva-Taneva, Olivera
    Dzekova-Vidimliski, Pavlina
    Trajceska, Lada
    Petronievic, Zvezdana
    Gelev, Saso
    Gjorgijevski, Nikola
    Tozija, Liljana
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [47] Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy
    Jorsal, A.
    Tarnow, L.
    Flyvbjerg, A.
    Parving, H. -H.
    Rossing, P.
    Rasmussen, L. M.
    DIABETOLOGIA, 2008, 51 (11) : 2100 - 2107
  • [48] Magnitude of End-Dialysis Overweight is Associated with All-Cause and Cardiovascular Mortality: A 3-Year Prospective Study
    Movilli, Ezio
    Camerini, Corrado
    Gaggia, Paola
    Zubani, Roberto
    Feller, Paolo
    Poiatti, Patrizia
    Pola, Alessandra
    Carli, Orsola
    Cancarini, Giovanni
    AMERICAN JOURNAL OF NEPHROLOGY, 2013, 37 (04) : 370 - 377
  • [49] Serum fructosamine and risk of cardiovascular and all-cause mortality: A 24-year prospective population-based study
    Zaccardi, F.
    Kurl, S.
    Pitocco, D.
    Ronkainen, K.
    Laukkanen, J. A.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2015, 25 (02) : 236 - 241
  • [50] EFFECT OF THE LONGER DURATION OF NEPHROLOGY REFERRAL ON ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN HEMODYALISIS PATIENRS: 5 YEAR PROSPECTIVE STUDY
    Selim, Gjulsen
    Stojceva-Taneva, Olivera
    Tozija, Liljana
    Georgievska-Ismail, Ljubica
    Gelev, Saso
    Dzekova-Vidimliski, Pavlina
    Trajceska, Lada
    Petronievic, Zvezdana
    Sikole, Aleksandar
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 446 - 446